Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From Boardroom to Benchtop: Paul LaViolette Joins SVLS

This article was originally published in Start Up

Executive Summary

Paul LaViolette spent more than a decade at Boston Scientific where, among other things, he helped build the company into a cardiovascular powerhouse. LaViolette announced his retirement from BSC last year and after considering a number of opportunities, decided to join Boston-based SVLS as a venture partner. LaViolette enters venture investing at a challenging time, during which the industry will face what he calls "a Darwinian process with more operational pressure" at start-ups and a likely weeding out of many companies. In this interview, LaViolette describes how the venture world of 2008 feels a lot like Boston Scientific in 1993 -- a world of small, driven companies with huge operational challenges and huge opportunities.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel